Curanex Pharmaceuticals (NASDAQ:CURX) Announces Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) issued its quarterly earnings results on Friday. The company reported ($1.86) EPS for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Trading Down 15.9%

NASDAQ CURX traded down $0.90 on Friday, reaching $4.77. The stock had a trading volume of 6,182 shares, compared to its average volume of 70,378. The business has a 50 day moving average price of $4.94 and a 200 day moving average price of $6.10. Curanex Pharmaceuticals has a 1 year low of $3.58 and a 1 year high of $13.33. The company has a market capitalization of $7.48 million, a price-to-earnings ratio of -0.61 and a beta of -2.99.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.